Develops cancer therapy candidates made from patients’ own immune cells, including engineered T-cell therapies for blood cancers and solid tumors.
10-K for FY2025, filed Mar 12, 2026We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor…View ↗
In hematologic malignancies, we are focused on delivering therapies that provide patients meaningfully improved outcomes over currently…View ↗
To realize the potential of cell therapy for solid tumors, in November 2025 we acquired an exclusive global license for LYL273 (excluding…View ↗
$36K
10-K for FY2025, filed Mar 12, 2026
$36K ↗No. It lost $274.4M in FY2025.
Shrinking. Revenue fell 100% in 4 years, from $10.7M in FY2021 to $36K in FY2025, about 76% a year.
A blood-cancer lead
The older report centered on proprietary T-cell reprogramming and a pipeline for solid tumors across CAR, TIL and TCR approaches. The latest report centers on CAR T-cell candidates for blood cancers, led by ronde-cel, alongside solid-tumor programs.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 12, 2026We are a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor…View ↗
In hematologic malignancies, we are focused on delivering therapies that provide patients meaningfully improved outcomes over currently…View ↗
To realize the potential of cell therapy for solid tumors, in November 2025 we acquired an exclusive global license for LYL273 (excluding…View ↗
Competes with Agenus, Akeso, Arcellx, Allogene Therapeutics, Arsenal Biosciences, AstraZeneca, Autolus Therapeutics, Bristol Myers Squibb, Caribou Biosciences, Gilead Sciences, Immunocore Holdings, Johnson & Johnson, Nanjing Legend Biotech, Novartis, Pfizer, Poseida, F. Hoffmann-La Roche, Summit Therapeutics, Amgen, and AbbVie
10-K for FY2025, filed Mar 12, 2026CAR T‑cell therapies for the treatment of hematologic malignancies and solid tumors are being developed by a number of companies, including…View ↗
Loading...